Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.96
+0.5%
$1.96
$1.42
$12.33
$71.51M1.34628,304 shs773,501 shs
Moderna, Inc. stock logo
MRNA
Moderna
$25.90
+2.0%
$26.29
$23.15
$138.07
$9.82B1.868.49 million shs13.76 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$6.41
+1.7%
$6.74
$5.01
$17.81
$1.02B2.86.46 million shs4.82 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$23.97
+0.4%
$23.26
$20.92
$31.54
$135.77B0.5741.38 million shs62.63 million shs
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$5.66
-1.1%
$6.39
$3.62
$8.66
$486.74M1.8142,658 shs11,596 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
+0.51%-2.00%-1.01%+2.08%-77.10%
Moderna, Inc. stock logo
MRNA
Moderna
+1.97%-2.89%+0.39%-20.70%-80.57%
Novavax, Inc. stock logo
NVAX
Novavax
+1.75%-7.64%-9.85%-15.66%-53.50%
Pfizer Inc. stock logo
PFE
Pfizer
+0.39%-2.22%+3.94%-8.53%-12.56%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-1.12%-5.89%-11.97%-21.12%-20.34%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
3.5448 of 5 stars
3.32.00.04.32.20.00.6
Moderna, Inc. stock logo
MRNA
Moderna
4.4687 of 5 stars
4.02.00.04.61.52.51.3
Novavax, Inc. stock logo
NVAX
Novavax
4.4042 of 5 stars
3.12.00.04.71.30.83.1
Pfizer Inc. stock logo
PFE
Pfizer
4.8771 of 5 stars
2.34.04.24.32.91.73.1
Valneva SE Sponsored ADR stock logo
VALN
Valneva
2.8424 of 5 stars
3.55.00.00.03.10.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50
Moderate Buy$9.75397.45% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.6179.97% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.29
Hold$17.00165.21% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.53
Moderate Buy$29.1721.69% Upside
Valneva SE Sponsored ADR stock logo
VALN
Valneva
3.00
Buy$15.50174.05% Upside

Current Analyst Ratings Breakdown

Latest NVAX, PFE, MRNA, VALN, and INO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Novavax, Inc. stock logo
NVAX
Novavax
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$6.00
6/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
5/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$33.00 ➝ $26.00
5/19/2025
Novavax, Inc. stock logo
NVAX
Novavax
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$5.00 ➝ $5.00
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $13.00
5/9/2025
Novavax, Inc. stock logo
NVAX
Novavax
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.00
5/8/2025
Valneva SE Sponsored ADR stock logo
VALN
Valneva
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$78.00 ➝ $70.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$45.00 ➝ $40.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$32.00 ➝ $28.00
(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$220K326.70N/AN/A$1.90 per share1.03
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.10N/AN/A$28.33 per share0.91
Novavax, Inc. stock logo
NVAX
Novavax
$1.21B0.85N/AN/A($3.89) per share-1.65
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.14$4.38 per share5.47$15.62 per share1.53
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$183.52M2.62$0.10 per share58.54$2.41 per share2.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$107.25M-$3.19N/AN/AN/AN/A-136.93%-89.99%8/6/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-105.67%-28.69%-21.94%7/30/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.652.4280.130.0738.14%-115.51%29.99%8/14/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.3817.377.910.8712.62%20.33%8.53%7/29/2025 (Estimated)
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-$13.25M-$1.19N/AN/AN/A-43.08%-43.05%-16.23%8/12/2025 (Estimated)

Latest NVAX, PFE, MRNA, VALN, and INO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.74-$0.51+$0.23-$0.51$0.01 million$0.07 million
5/8/2025Q1 2025
Novavax, Inc. stock logo
NVAX
Novavax
$0.71$2.93+$2.22$2.93$204.08 million$666.66 million
5/7/2025Q1 2025
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-$0.40-$0.13+$0.27-$0.13$41.80 million$51.79 million
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.18%N/A124.64%16 Years
Valneva SE Sponsored ADR stock logo
VALN
Valneva
N/AN/AN/AN/AN/A

Latest NVAX, PFE, MRNA, VALN, and INO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
2.63
2.63
Moderna, Inc. stock logo
MRNA
Moderna
N/A
4.22
4.14
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.06
2.03
Pfizer Inc. stock logo
PFE
Pfizer
0.64
1.26
0.96
Valneva SE Sponsored ADR stock logo
VALN
Valneva
0.92
2.70
2.12

Institutional Ownership

CompanyInstitutional Ownership
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
11.39%

Insider Ownership

CompanyInsider Ownership
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.30%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
14.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32036.67 million35.83 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800386.74 million344.20 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990161.97 million160.35 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable
Valneva SE Sponsored ADR stock logo
VALN
Valneva
70085.09 million72.41 millionNot Optionable

Recent News About These Companies

US Advises Older Travelers to Avoid Chikungunya Vaccine

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.96 +0.01 (+0.51%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$1.96 0.00 (-0.26%)
As of 06/20/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Moderna stock logo

Moderna NASDAQ:MRNA

$25.90 +0.50 (+1.97%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$25.93 +0.03 (+0.12%)
As of 06/20/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax stock logo

Novavax NASDAQ:NVAX

$6.41 +0.11 (+1.75%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$6.40 0.00 (-0.08%)
As of 06/20/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer stock logo

Pfizer NYSE:PFE

$23.97 +0.09 (+0.37%)
Closing price 06/20/2025 03:59 PM Eastern
Extended Trading
$23.99 +0.02 (+0.09%)
As of 06/20/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Valneva stock logo

Valneva NASDAQ:VALN

$5.66 -0.06 (-1.12%)
Closing price 06/20/2025 03:58 PM Eastern
Extended Trading
$5.66 0.00 (0.00%)
As of 06/20/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.